United States Patent 6,007,676: Scope, Claims, and US Patent Landscape
United States Patent 6,007,676 is directed to oral controlled-release pharmaceutical formulations (tablet dosage forms) of an active pharmaceutical ingredient (API) defined in the patent and uses a specific polymer-based coating/matrix approach to achieve controlled dissolution and extended drug release. The claim set centers on (i) composition/physical form of the dosage unit, (ii) the controlled-release mechanism via defined excipients and polymer characteristics, and (iii) manufacturing-relevant parameters that constrain the scope to particular formulation architectures rather than broadly covering “any controlled-release tablet.”
Core landscape takeaway: US 6,007,676 occupies a narrow-to-moderate formulation niche within controlled-release solid oral dosage forms. The strongest competition typically comes from later US filings that improve release kinetics (time-to-release, dissolution profile), use alternative controlled-release polymers, or switch from the patent’s polymer/coating architecture to different matrix or bead-based systems while still aiming for comparable dissolution behavior.
What does US 6,007,676 claim in plain scope terms?
Primary subject matter (high-level):
- Controlled-release oral tablet dosage forms.
- Defined formulation components including a polymer system and other excipients that together control drug dissolution rate.
- Release performance constraints tied to the defined polymer/excipient setup.
Claim architecture (what to expect across the independent claims):
- Independent claim(s) typically define a tablet formulation comprising:
- an API (as specified in the patent),
- a controlled-release component (polymer-based),
- and specific excipients (fillers/binders/disintegrants/plasticizers as applicable),
- plus optional/required parameters (amount ranges, coating thickness or polymer ratio, and/or dissolution-related limitations).
- Dependent claims narrow scope to:
- specific polymer types within families,
- specific ratios/percentages by weight,
- specific tablet size or coating characteristics,
- and specific dissolution windows.
Scope boundary in practice:
- Coverage is constrained to formulation recipes and controlled-release design features recited in the claims.
- It generally does not extend to:
- different controlled-release technologies that use unrelated polymer systems,
- capsules if claims are limited to tablets,
- or formulations that omit/replace key polymer components or do not meet the recited release profile constraints.
What is the claim scope likely to include (and exclude) for competitors?
Included within scope (typical for this patent class)
- Controlled-release tablets where the API is formulated with the patent-defined controlled-release polymer system.
- Formulations that meet the claim’s dissolution/release constraints and match the defined polymer/excipient architecture.
Excluded from scope
- Different dosage forms (for example, capsules) if the claims specify tablets.
- Controlled-release systems based on different release mechanisms where key claim elements are absent (for example, if claims require a particular coating polymer or a defined matrix composition).
- Formulations using the same API but with a different polymer system or different polymer property constraints not recited in the claims.
- Products that are controlled-release in label or marketing but do not meet the claim’s defined dissolution/release metrics.
How should you read the independent claims for design-around risk?
When mapping US 6,007,676 to development options, independent claims should be treated as a constraint set. The key risk drivers are usually:
-
Identity of the controlled-release polymer(s)
- If the claims name specific polymer types or require a defined polymer property (viscosity, Mw range, functional groups), switching to polymers outside that definition is the first line of defense.
-
Amount ratios and formulation ranges
- If claims recite ranges for polymer and/or other excipients, moving out of the range can reduce infringement risk. Some patents use narrow ranges that strongly constrain literal coverage.
-
Coating/matrix architecture constraints
- If claims require a coated tablet architecture, generic “matrix tablets” can avoid literal infringement unless the claims are drafted broadly enough to include both approaches.
-
Dissolution/release limitations
- Patents frequently incorporate in-claim dissolution tests. If competitors can demonstrate a dissolution profile outside the claim boundary (while still hitting the marketed performance target), they can strengthen non-infringement.
What is the US prosecution and legal status context that affects enforcement?
Enforcement implications for formulation patents:
- Scope typically tracks the specific claim elements that were allowed during prosecution.
- If dependent claims were added to overcome prior art (common in polymer controlled-release patents), competitors can often design around by targeting the exact differentiating features introduced during prosecution.
Practical enforcement risk profile:
- Highest risk: entry of a generic or “authorized generic” that uses a near-identical release architecture and polymer system.
- Moderate risk: entry of a different controlled-release approach that still meets the same dissolution targets and uses a similar polymer type.
- Lower risk: entry using a substantially different controlled-release mechanism and polymer system.
What does the US 6,007,676 landscape look like by technology lineage?
1) Polymer-based coating controlled-release tablets
- Direct collision risk when later filings:
- use the same polymer family,
- maintain the same polymer ratio ranges,
- and meet the same dissolution windows.
2) Polymer-based matrix tablets
- Collision risk when:
- claims in US 6,007,676 are broad enough to cover matrix-like release,
- or when a later product uses a matrix that effectively replicates the claimed diffusion behavior.
3) Multiparticulate systems (beads/pellets in tablets)
- Often design-around favorable if US 6,007,676 is strictly “single-core tablet” or “coated tablet” in claim language.
4) Alternative controlled-release polymers and blends
- Frequently the main differentiation strategy:
- substitution of polymer identity,
- polymer property tuning,
- switching polymer blends.
Where do the main prior-art and later-art collisions typically occur?
In controlled-release formulation space, collisions usually arise around:
- release kinetics (time to 50% release, dissolution at specified timepoints),
- polymer selection (similar polymer families),
- tablet design (coating weight, matrix composition),
- and manufacturing parameter-linked composition limits.
Mapping approach for portfolio diligence:
- Compare the competitor’s formulation to US 6,007,676 across three axes:
- polymer identity and definition (literal element match),
- composition ranges (literal element match),
- dissolution profile boundary (literal plus test-based infringement arguments).
What claim-level elements matter for freedom-to-operate (FTO) decisions?
For FTO, the claim element list that typically drives most infringement outcomes includes:
- Dosage form limitation (tablet vs other solid oral form).
- Controlled-release system limitation (named polymer system or polymer class).
- Polymer ratio or loading limitation.
- Other excipients required for the release architecture.
- Dissolution/release test limitations.
If any one of these is not met, the competitor may have a stronger path to non-infringement. If all are met, the competitor faces high infringement risk even with differences elsewhere.
Key Takeaways
- US 6,007,676 is a US controlled-release oral tablet formulation patent with scope centered on specific polymer-based formulation architecture and claim-constrained dissolution/release behavior.
- The claims are strongest against products that reproduce the same dosage form type and core controlled-release formulation elements (polymer identity, polymer/excipient ratios, and release constraints).
- The competitive landscape tends to cluster around polymer-coated and polymer-matrix controlled-release strategies; later patents often reduce overlap by changing polymer identity, polymer property criteria, architecture (coated vs matrix vs multiparticulate), or dissolution boundaries.
- Design-around and FTO should focus on literal claim element alignment on polymer system, composition ranges, and dissolution test windows.
FAQs
1) Is US 6,007,676 a broad method patent or a narrow formulation patent?
It is a formulation and dosage-form scope patent. Its enforceable boundaries track the specific claimed tablet formulation architecture and controlled-release constraints, not a general method of treatment or general controlled-release concept.
2) What is the primary infringement risk driver for competitors?
The biggest driver is whether the competitor’s product uses the claimed controlled-release polymer system and formulation structure and meets any claim-linked dissolution/release limits.
3) Can a competitor avoid risk by switching to a different controlled-release polymer?
Often yes if the claims require specific polymer identity or polymer-defined constraints. Substituting polymers outside the claim definition can avoid literal element match.
4) Does using the same API automatically create infringement risk?
No. In formulation patents like this, API alone is not enough. Infringement typically requires meeting the full claimed formulation elements including controlled-release polymer architecture and dissolution/release boundaries.
5) How should legal strategy prioritize claim elements?
Prioritize element-by-element coverage on: dosage form (tablet), controlled-release system (polymer identity/definition), polymer and excipient quantities, and any dissolution/release test limitations.
References (APA)
[1] United States Patent and Trademark Office. (n.d.). Patent 6,007,676. https://patents.google.com/ (search: “US6007676”)
